Get started
Author

Po Chung Chan

Observed names: Chan, Po Chung, P.C. Chan, Po Chan, Po Chung Sunny Chan
ORCID: 0009-0008-6355-8147
Observed ORCID: 0009-0008-6355-8147
OpenAlex ID: A5110647384
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2021 · Caroline Even, Hung-Ming Wang, et al. · Clinical Cancer Research · 68
PDF
Post-operative radiotherapy for oral cavity squamous cell carcinoma: Review of the data guiding the selection and the delineation of post-operative target volumes
2025 · Mererid Evans, Pierluigi Bonomo, et al. · Radiotherapy and Oncology · 32
PDF
The use of ketamine in the management of refractory cancer pain in a palliative care unit
2019 · Ka Wai Alice Cheung, Po Chung Chan, et al. · Annals of Palliative Medicine · 31
PDF
Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC)
2019 · Darren Wan-Teck Lim, Hung-Ming Wang, et al. · Cancer Research · 16
Patterns and infection outcomes of bacterial colonization in patients with indwelling abdominal drains for malignant ascites
2020 · Po Chung Chan, Ka Wai Alice Cheung, et al. · Annals of Palliative Medicine · 12
PDF
Comparing respiratory polygraphy with pulse transit time analysis versus overnight polysomnography in the diagnosis of obstructive sleep apnoea in children
2021 · Tammy WY. Cheung, David SY. Lam, et al. · Sleep Medicine · 10
Delineation of the post-operative primary tumour and nodal clinical target volumes in oral cavity squamous cell carcinoma: European Society for Radiotherapy and Oncology (ESTRO) clinical guidelines
2025 · Mererid Evans, Pierluigi Bonomo, et al. · Radiotherapy and Oncology · 9
No Role of Using Chemoradiation in T2N0 and T1N1 With Small Lymph Node Size Stage II Nasopharyngeal Carcinoma
2015 · A.W.Y. Ng, S.Y. Tung, et al. · International Journal of Radiation Oncology*Biology*Physics · 3
PDF
Antitumor activity of bintrafusp alfa in previously treated patients with recurrent or metastatic nasopharyngeal cancer (NPC): A single arm, prospective phase II trial.
2022 · Chi Leung Chiang, Tai Chung Lam, et al. · Journal of Clinical Oncology · 2
How common is indwelling abdominal drain-related infection—no simple answer
2020 · Po Chung Chan, Ka Wai Alice Cheung, et al. · Annals of Palliative Medicine · 1
147 Review of patients with metastatic and locally advanced NSCLC who receive 2 years of palliative pembrolizumab with or without chemotherapy
2026 · Mick Button, Sally Fouda, et al. · Lung Cancer
190 High dose palliative radiotherapy in NSCLC: a retrospective review of dose fractionation and outcomes
2026 · Sarah Walters, Gwenllian Edwards, et al. · Lung Cancer
Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Data from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Figure 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Figure 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 5 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 3 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 4 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 7 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 7 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Supplementary Table 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
2023 · Caroline Even, Hung-Ming Wang, et al.
Works count: 29
Citation count: 184
H-index: 7
I10-index: 6
Year
Topic
Type